ItsHerWay launches UAE's first miscarriage bereavement leave pledge, urging companies to support grieving parents
UAE — In a bold move to address a silent workplace injustice, UAE-based women's platform ItsHerWay has launched The Leave of Absence the first corporate pledge in the region calling on companies to introduce formal bereavement leave for employees who have experienced a miscarriage.
More than 1 in 5 pregnancies worldwide end in miscarriage — a statistic that holds true in the UAE. Yet, despite the scale of this experience, it remains largely unspoken in the workplace. In fact, 95% of women (and men) in the UAE who have experienced a miscarriage while employed reported taking no leave days off work to recover from the grief. While some policies may exist, the issue often lies in inconsistent implementation, a lack of clarity around entitlements, or simply the discomfort of bringing up something so personal in a professional environment. And in that silence, one thing becomes clear: the loss of a child before birth is often not treated as a loss at all.
The Leave of Absence pledge aims to change this, calling on companies to recognise the deep pain and loss that comes with a miscarriage and implement compassionate bereavement policies that offer parents time to heal.
Companies can now sign the pledge and join a movement that aims to shift corporate culture across the region and beyond.
Armin Jamula, Co-Founder of ItsHerWay said: 'Leave of Absence sheds light on a topic often left unspoken in our region. When parents are expected to return to work the day after a miscarriage, it reveals a painful blind spot in corporate empathy. Our pledge is a call to action, to normalize such an important dialogue and encourage actionable change that offers both women and men the space to process their grief after loss.'
The initiative is already gaining traction, with businesses and HR leaders across the UAE expressing interest in adopting the policy. Companies can download a template of the pledge from http://theleaveofabsence.com/ and submit to their own HR departments. It's also where heads of companies can sign the pledge to show their support for the cause and implement miscarriage leave for both women and men.
Raising Awareness Through Storytelling
To support the initiative, ItsHerWay has launched an emotional awareness campaign, featuring a short film titled The Needed Space. The film offers a deeply moving portrayal of life after miscarriage. Not through people but through fragments of many homes, each caught in a different chapter of parenthood-in-waiting: an untouched crib, folded baby clothes, sterilised bottles. All symbols of love paused in time.
Set to a lullaby-like rendition of 'Sweet Child O' Mine,' the film has been created to evoke empathy and encourage corporate leaders to reconsider outdated policies around parental loss. Watch it here- https://www.youtube.com/watch?v=cHWahwstEow.
The campaign also includes a series of disguised Facebook Marketplace-style ads with listings for never-used baby items like onesies and nursery furniture. The asking price? Compassionate leave.
Companies can sign up to the pledge via http://theleaveofabsence.com/
About ItsHerWay
ItsHerWay is a fast-growing platform in the UAE that supports women through every phase of their professional journeys — from entrepreneurship and funding to emotional well-being and workplace equity. Known for launching bold, socially resonant campaigns, ItsHerWay continues to use its platform to challenge taboos, spark dialogue, and drive meaningful change.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
43 minutes ago
- Zawya
New Mayo Venture Partner program announced to accelerate innovation
Dubai, United Arab Emirates — Mayo Clinic's Business Development team, consistently recognized as one of the top commercialization operations among academic medical centers, is expanding its capabilities through a new initiative: the Mayo Venture Partner (MVP) program. In response to the dynamic and evolving healthcare landscape, Mayo Clinic is enlisting industry veterans to create groundbreaking technologies, co-invest in aligned companies and build new ventures from the ground up. The MVP program brings together seasoned entrepreneurs, investors and executives who will leverage their expertise with Mayo Clinic's world-class research and clinical expertise. These leaders will play a pivotal role in identifying high-potential opportunities across Mayo Clinic's research and clinical practices, forming new companies and accelerating innovations that advance patient care. The inaugural MVPs are: Amy DuRoss — Healthcare innovation leader with deep expertise in policy, commercialization and diagnostics. Audrey Greenberg — Company builder, executive leader and expert in launching and scaling ventures across life sciences, healthcare and other industries. Brian Poger — Serial entrepreneur and venture strategist with a track record in digital health and healthcare services. Working in close partnership with the Mayo Clinic Business Development team, the MVPs will help forge strategic collaborations and deliver real-world impact, underscoring Mayo Clinic's enduring commitment to transforming healthcare. To date, the Business Development team has returned more than $1.2B in revenue to Mayo Clinic to support its clinical practice, education and research. Additionally, the team has helped create more than 180 companies, licensed 4,848 Mayo Clinic-created technologies through 2,913 agreements, and issued 4,159 patents. This program and these efforts align with Mayo Clinic's vision to transform healthcare by: Accelerating innovation — Turning cutting-edge research, data and other resources into real-world solutions for patients. Enhancing patient care — Bringing new treatments and technologies to patients that offer cures and the ability to connect with the healthcare system in ways that increase access and decrease costs. Building strategic partnerships — Leveraging external expertise and resources to amplify impact. Mayo Clinic is dedicated to driving progress and expanding its impact through innovation. This initiative is an exciting opportunity for investors, CEOs and innovators to collaborate with Mayo Clinic and be part of a future that prioritizes patient-centric, transformative healthcare solutions. To learn more, visit the Mayo Clinic Business Development website and subscribe to its e-newsletter and follow the Mayo Clinic Ventures LinkedIn page.
Arabian Business
2 hours ago
- Arabian Business
‘Not a magic solution': UAE doctors warn of surging off-label use of Ozempic, Mounjaro for weight loss
Doctors in the United Arab Emirates are warning against the growing off-label use of diabetes medications such as Ozempic and Mounjaro for weight loss, as demand surges among individuals who are neither diabetic nor clinically obese. Originally developed to treat type 2 diabetes, GLP-1 receptor agonists – semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) – are now increasingly being used for aesthetic weight loss purposes in the UAE, reflecting a broader global phenomenon that experts say may be spiralling beyond medical control. 'Some are seeking these medications purely for weight loss,' Dr Tony Joseph, a specialist endocrinologist at Burjeel Day Surgery Center in Al Shahama, told Arabian Business. 'For patients without obesity or metabolic disease, the risk-benefit ratio is unclear.' Joseph added that while prescriptions in his clinic remain within approved indications – obesity (a Body Mass Index of 30 or higher, or 27 or higher in individuals with weight-related comorbidities) and type 2 diabetes – the uptick in off-label interest has been notable. The medications have rapidly gained popularity due to their visible results, with some patients losing more than 15 per cent of body weight in under a year. But healthcare professionals are urging caution. The misuse of these drugs outside clinical guidelines may expose some to side effects ranging from nausea and gastrointestinal discomfort to more serious complications such as pancreatitis, gallbladder issues, and potential muscle loss. 'Long-term safety in non-obese individuals has not been well established in clinical trials,' Joseph said. 'We advise caution.' Social media hype fueling 'quick fix' culture Clinical dietitians say the surge in demand is being driven not by medical referrals, but by viral social media content glamorising the drugs as easy, injectable solutions to weight loss. 'Few social media platforms have glamorised these drugs, often portraying them as magical solutions,' Ruqsar Rahman, a clinical dietitian at Burjeel Hospital in Abu Dhabi, told Arabian Business. 'This undermines the importance of long-term nutrition and physical activity.' Rahman noted a marked shift in how patients approach weight loss, with more inquiries about pharmaceuticals and fewer about dietary planning or physical training. 'The availability of these drugs has created the perception of a quick fix,' she said. 'We're seeing people bypass the fundamentals – like sustainable eating and movement – in favour of weekly injections.' Dependency and weight regain risks Even when prescribed appropriately, GLP-1 receptor agonists pose another challenge: maintaining weight loss once treatment stops. Both Joseph and Rahman have observed patients regaining weight after discontinuation, particularly if lifestyle changes weren't made in parallel. 'Without long-term behaviour change, weight regain is typical once the medication is stopped,' said Joseph. 'This is one of the biggest challenges we face in practice.' Rahman likens the pattern to crash dieting, with dramatic short-term results often followed by a swift return to previous weight. 'When individuals haven't built sustainable habits to support the weight loss, the weight often returns,' she said. 'The drugs should be a stepping stone, not a lifelong crutch.' Clinical promise – if used ethically Despite concerns about misuse, both experts emphasised that GLP-1 drugs represent a genuine breakthrough in treating obesity – particularly in regions like the Gulf, where sedentary lifestyles and diet-related diseases are widespread. 'These medications are not a silver bullet, but they are a powerful tool,' Joseph said. 'They help bridge the gap where lifestyle interventions alone have had limited success.' Used within a comprehensive care plan that includes dietary support, physical activity, and mental health counselling, the drugs can help patients achieve long-term success. At his clinic, Joseph refers eligible patients to a multidisciplinary team to ensure a tailored and safe weight management strategy. Rahman agreed, adding that the drugs should be framed as part of an evidence-based medical toolkit, not as cosmetic enhancements. 'When paired with improved nutrition, exercise, and emotional health support, the outcomes can be dramatically improved,' she said. 'But if we position them as cultural shortcuts, we do more harm than good.' The UAE Ministry of Health and Prevention (MOHAP) has reiterated that GLP-1 drugs are prescription medications and should only be used under medical supervision. Physicians are required to follow established clinical protocols, including those issued by the American Diabetes Association (ADA) and the European Association for the Study of Obesity (EASO). As interest in weight-loss injections continues to grow, doctors in the Emirates are calling for stronger regulation, better patient education, and a renewed focus on prevention over treatment. 'Obesity is a chronic, relapsing disease with both biological and environmental drivers,' Joseph said. 'The emergence of practical pharmacological tools is welcome, but we must ensure they are used responsibly, ethically, and with patient safety as the top priority.'
Zawya
2 hours ago
- Zawya
CorroHealth makes strategic investment in Gulf Capital's Santechture
Abu Dhabi – Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that global healthcare technology company CorroHealth has made a strategic investment into one of its portfolio companies, Santechture, a Dubai based pioneering revenue cycle management (RCM) intelligent technology solutions provider. The deal brings together the industry-leading AI capabilities of CorroHealth with the advanced RCM solutions of SANTECHTURE, equipping SANTECHTURE healthcare clients across the Gulf Cooperation Council (GCC) region with powerful new technology to maximize ROI. The investment formalizes what has been a productive working relationship between the two companies. Over the past two years, CorroHealth and SANTECHTURE have successfully completed multiple proofs of concept for SANTCEHTURE clients. In January, SANTECHTURE and CorroHealth jointly hosted the Arab Health reception focused on AI and Revenue Cycle Management (RCM) Innovation. SANTECHTURE, which is backed by leading institutional investors Gulf Capital and Shorooq Partners, has seen a phenomenal increase in demand for its advanced deep tech RCM solutions in the GGC and across regional markets, and this partnership will support yet another leap ahead in advancing innovation and value creation. CorroHealth CEO Pat Leonard said, 'This is an exciting step forward for CorroHealth, as we combine our technological capabilities with a local company based in the GCC region. CorroHealth joining forces with SANTECHTURE brings the best of both worlds to provide clients in the region with unsurpassed RCM capabilities to protect hospitals' bottom lines and help to ensure their financial future.' SANTECHTURE Founder and CEO Anas Batikhi said, 'The pairing of SANTECHTURE's unique leading-edge solutions with CorroHealth's AI driven innovations in the RCM technology space is truly unrivalled. We are especially thrilled to be cementing further our working relationship with CorroHealth and leading the intelligent automation drive to support our clients and partners with their RCM digital transformation journey, delivering on cost reduction and improved revenue outcomes.' Gulf Capital Managing Director Mohammad Madani added, 'We are proud to have been early backers of SANTECHTURE and to now support this landmark partnership between SANTECHTURE's and CorroHealth. This strategic investment is a strong validation of SANTECHTURE's leadership in intelligent RCM solutions across the GCC and marks a pivotal milestone in its growth journey. We are confident this collaboration will unlock significant value for healthcare providers in the region.' Bilal Mushtaq, MD, CorroHealth's Executive Vice President of Global Growth and Strategy for GCC market expansion said 'This strategic investment and partnership marks a pivotal step forward in our growth strategy, reinforcing our commitment to innovation and delivering greater value to a new market. This is not just a collaboration but a shared vision to forge a new path towards providing excellence in revenue cycle management'
